Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT00544284
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸City of Hope Medical Group, Pasadena, California, United States
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT00541359
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope Medical Group Inc, Pasadena, California, United States
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00538187
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT00536575
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 46
- Registration Number
- NCT00523848
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
- Conditions
- Interventions
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00522392
- Locations
- 🇺🇸
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States
🇺🇸Illinois Oncology Research Association CCOP, Peoria, Illinois, United States
🇺🇸Saint Francis Hospital and Health Centers, Beech Grove, Indiana, United States
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT00520767
- Locations
- 🇺🇸
Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States
🇺🇸Boston University Cancer Research Center, Boston, Massachusetts, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC
- Conditions
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- Aptium Oncology Research Network
- Target Recruit Count
- 62
- Registration Number
- NCT00516100
- Locations
- 🇺🇸
Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States
🇺🇸Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey, United States
🇺🇸Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, United States
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 33
- Registration Number
- NCT00513877
- Locations
- 🇮🇪
Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital, Dublin, Ireland
🇧🇪Universitair Ziekenhuis Gent, Ghent, Belgium
🇮🇪Cork University Hospital, Cork, Ireland
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2014-11-05
- Lead Sponsor
- University Hospital Plymouth NHS Trust
- Target Recruit Count
- 50
- Registration Number
- NCT00513955
- Locations
- 🇬🇧
Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom
🇬🇧Birmingham Heartlands Hospital, Birmingham, England, United Kingdom
🇬🇧Addenbrooke's Hospital, Cambridge, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.